# Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria

> **NCT03392896** · PHASE1 · COMPLETED · sponsor: **Dicerna Pharmaceuticals, Inc., a Novo Nordisk company** · enrollment: 43 (actual)

## Conditions studied

- Primary Hyperoxaluria

## Interventions

- **DRUG:** DCR-PHXC
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03392896
- **Lead sponsor:** Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-06
- **Primary completion:** 2019-11-19
- **Final completion:** 2019-11-19
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03392896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03392896, "Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03392896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*